Floatz logo

AGONISTIC ANTI-CD40 MONOCLONAL ANTIBODY ADC-1013

Advanced Solid Neoplasms

Janssen Research & Development, LLCmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced Solid Neoplasms cohort.

Asset / SponsorPhaseRating
Olaparib
Merck Sharp & Dohme LLC
Phase 2CCC
Tak-659
Calithera Biosciences, Inc
Phase 1D

Same molecule, other indications

AGONISTIC ANTI-CD40 MONOCLONAL ANTIBODY ADC-1013 is also rated in:

neoplasmDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →